Portfolio company
ARTHEx Biotech
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This clinical-stage biotechnology company develops RNA-based treatments for patients with rare neuromuscular genetic diseases, including myotonic dystrophy type 1.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Dyne Therapeutics
The company develops oligonucleotide therapeutics to treat patients with genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1.
DTX Pharma
This biotechnology firm develops RNA-based therapeutics for patients with rare neuromuscular and central nervous system disorders using a proprietary fatty acid delivery platform.
ADARx Pharmaceuticals
This clinical-stage biotechnology company develops RNA-targeting therapeutics for patients with genetic, cardiometabolic, complement-mediated, and central nervous system diseases.
Design Therapeutics
Design Therapeutics develops small-molecule therapies for patients with serious degenerative genetic diseases, including Friedreich ataxia and myotonic dystrophy type-1.
Armatus
The company develops vectorized RNAi therapeutics to treat genetic neurological and neuromuscular diseases for patients with rare conditions.
Phlox Therapeutics
This company develops RNA-based gene therapies to treat patients with rare genetic heart diseases, including cardiomyopathies and laminopathies.
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
Typewriter Therapeutics
The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.